Your browser is no longer supported. Please, upgrade your browser.
Settings
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.68 Insider Own0.20% Shs Outstand113.16M Perf Week-18.98%
Market Cap3.43B Forward P/E- EPS next Y-1.17 Insider Trans- Shs Float112.91M Perf Month-13.18%
Income-173.80M PEG- EPS next Q-0.49 Inst Own99.20% Short Float18.14% Perf Quarter27.26%
Sales0.06M P/S56208.98 EPS this Y-71.80% Inst Trans12.83% Short Ratio5.77 Perf Half Y-13.58%
Book/sh4.00 P/B7.57 EPS next Y31.20% ROA-57.50% Target Price45.70 Perf Year-27.74%
Cash/sh4.04 P/C7.50 EPS next 5Y- ROE-61.60% 52W Range16.64 - 51.99 Perf YTD-15.01%
Dividend- P/FCF- EPS past 5Y-43.90% ROI- 52W High-41.72% Beta3.45
Dividend %- Quick Ratio21.90 Sales past 5Y- Gross Margin- 52W Low82.09% ATR1.92
Employees320 Current Ratio21.90 Sales Q/Q- Oper. Margin- RSI (14)31.39 Volatility7.60% 5.43%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.90% Profit Margin- Rel Volume0.79 Prev Close31.43
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume3.55M Price30.30
Recom2.10 SMA20-18.56% SMA50-10.84% SMA200-1.95% Volume2,787,990 Change-3.60%
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-03-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-30-16Reiterated Piper Jaffray Overweight $39 → $44
Feb-08-16Initiated BofA/Merrill Buy $40
Jan-22-16Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Upgrade Piper Jaffray Neutral → Overweight $48
Aug-07-15Reiterated Needham Buy $38 → $49
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
Apr-16-15Initiated Leerink Partners Outperform $48
Mar-12-15Reiterated Needham Buy $40 → $38
Feb-24-15Initiated H.C. Wainwright Buy $50
Feb-06-15Resumed ROTH Capital Buy $42
Dec-22-14Reiterated Needham Buy $26 → $40
Aug-07-13Reiterated Needham Buy $16 → $26
Aug-07-13Reiterated Ladenburg Thalmann Buy $15 → $24
Aug-07-13Downgrade MLV & Co Buy → Hold $18 → $20
Apr-11-13Reiterated Needham Buy $9 → $16
Apr-11-13Reiterated MLV & Co Buy $12.50 → $18
Apr-11-13Reiterated Ladenburg Thalmann Buy $9 → $15
Mar-13-13Reiterated Ladenburg Thalmann Buy $8 → $9
Jun-27-16 09:00AM  ACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index Business Wire
Jun-22-16 08:07AM  Analysts' Actions -- Domino's, McDonald's, Priceline, Tesla and More
07:16AM  ACADIA Pharmaceuticals downgraded by BofA/Merrill
Jun-21-16 12:32PM  S&P 500s technical backdrop remains bullish-leaning pending Brexit vote at MarketWatch -6.44%
Jun-17-16 07:16AM  Limited upside seen for Acadia Pharma
Jun-16-16 09:05AM  Analyzing IBBs Moving Averages
09:00AM  ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016 Business Wire
Jun-12-16 06:43AM  Is Acadia Pharmaceuticals' Stock Still a Buy? at Motley Fool
Jun-10-16 05:10PM  ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
Jun-08-16 02:09PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 8, 2016
Jun-06-16 04:30PM  Why Shares of ACADIA Pharmaceuticals Inc. Jumped Today at Motley Fool +12.78%
Jun-01-16 09:00AM  ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016 Business Wire
May-31-16 05:58PM  What Happened to Ioniss Revenues in 1Q16?
08:00AM  ACADIA Pharmaceuticals Announces NUPLAZID (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinsons Disease Psychosis Business Wire
May-27-16 08:33AM  Delayed FDA Decision Sends Sarepta Therapeutics Soaring
May-26-16 06:00AM  'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway
May-25-16 09:07AM  XBIs and IHIs Mid-Caps Soared, Overturning 2 Weeks of Losses
May-20-16 09:06AM  Pfizer, Biogen Can Fancy Acadia for Takeover
May-18-16 10:16PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : May 19, 2016
May-17-16 01:45PM  ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q1, 2016 By the Numbers +5.59%
May-16-16 09:00AM  Sarepta's AdCom Needs FDA's Permission To Speak Freely at Forbes +6.83%
May-12-16 01:04PM  ACADIA PHARMACEUTICALS INC Financials
May-11-16 07:00PM  Cramer: I suspect this stock is a classic value trap at CNBC
May-10-16 07:45AM  Merrill Lynch Has 3 Top BioPharma Picks to Win From the Aging of America at 24/7 Wall St.
May-09-16 02:00PM  Acadia Pharmaceutical's Nuplazid Pricing Is Good News for Shareholders at TheStreet +5.79%
May-06-16 01:05PM  Edited Transcript of ACAD earnings conference call or presentation 5-May-16 9:00pm GMT
May-05-16 05:44PM  Acadia reports 1Q loss
05:02PM  Acadia (ACAD) Stock Slides in After-Hours Trading on Q1 Financial Results at TheStreet
05:00PM  ACADIA Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today CCBN
04:18PM  ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
04:05PM  ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results Business Wire
11:22AM  Acadia Drug Approval May Entice Biogen, Teva as Buyers The Deal Pipeline
07:07AM  Q1 2016 ACADIA Pharmaceuticals Inc Earnings Release - After Market Close CCBN
May-04-16 02:17PM  Acadia Pharmaceuticals Stock Has Fallen Too Far Recently at TheStreet -8.23%
09:01AM  ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016 Business Wire
08:22AM  Why ACADIA Pharmaceuticals Inc Jumped 12.7% in April at Motley Fool
May-03-16 04:43PM  ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta EDGAR Online -9.09%
01:50PM  Put the trade on......NOW Yahoo Finance Contributors
10:03AM  Why Acadia Pharma's First Drug Approval Isn't Moving Stock Higher at TheStreet
08:22AM  8 Stocks Spiking on Big Volume at TheStreet
08:12AM  Analysts' Actions -- Amazon, Walmart, Acadia, International Paper and More TheStreet
May-02-16 04:14PM  Investors Await Pricing of Acadia's Recently Approved Parkinson's Drug at TheStreet
04:01PM  ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016 Business Wire
02:08PM  FDA approves drug to treat highly disruptive symptom of Parkinsons disease at MarketWatch
11:34AM  ACADIA Pharmaceuticals (ACAD) Stock Down Despite Nuplazid Approval at TheStreet
11:10AM  An antidote to trading on tilt Yahoo Finance Contributors
08:38AM  A drug that could change the way we treat Parkinson's disease just got approved Business Insider
08:30AM  ACADIA Pharmaceuticals Inc to discuss the FDA approval of NUPLAZID Call scheduled for 8:30 am ET today CCBN
02:16AM  Trending Now: ACAD Yahoo Finance - Qwiki
Apr-30-16 08:02AM  3 All-or-Nothing Stocks To Watch Closely at Motley Fool
Apr-29-16 07:17PM  FDA Approves ACADIA Pharmaceuticals NUPLAZID (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinsons Disease Psychosis Business Wire
06:26PM  U.S. approves first drug for psychosis linked to Parkinson's Reuters
05:55PM  First drug for delusions in Parkinson's patients approved AP
05:38PM  U.S. approves Acadia drug for Parkinson's disease-linked psychosis Reuters
Apr-28-16 12:59PM  Acadia drug approval could clear way for Axovant dementia therapy Reuters
Apr-25-16 08:14AM  Acadia Pharma faces downside position optionMONSTER
Apr-23-16 03:00PM  Billionaires Love These 3 Stocks -- But Are They Right for You? at Motley Fool
Apr-18-16 09:41AM  3 Stocks That Could Double Your Money at Motley Fool
Apr-10-16 10:05AM  Massive Biotech Insider Buy Highlights Volatile Trading Week: Acadia, Conns, William Lyon, Summit Midstream and More at 24/7 Wall St.
Apr-09-16 10:00AM  3 Stocks the Smartest Investors Are Buying Now at Motley Fool
12:06AM  XBI Mid Caps: Alnylam to Present at Needham Healthcare Conference
Apr-08-16 08:04AM  Why ACADIA Pharmaceuticals Inc Skyrocketed 46% Higher in March at Motley Fool
Apr-07-16 04:07PM  Incyte Continues Its Growth Spree in 2015
Apr-06-16 04:27PM  Here's Why Sarepta Therapeutics Jumped Today at Motley Fool +9.90%
10:08AM  Anacor Pharmaceuticals: $250 Million in Convertible Senior Notes
09:00AM  ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016 Business Wire
Apr-05-16 10:36AM  Biotechnology ETFs: Who Were the Top Performers Last Week?
Apr-04-16 02:27PM  These 4 Healthcare Stocks Are All Soaring Today, and Here's Why at Motley Fool
10:21AM  Podcast: How to find your trading edge
Apr-03-16 10:20AM  Top 6 Biopharma Movers of the Past Week at 24/7 Wall St.
09:00AM  Biotech Stock Mailbag: Intercept, Acadia, Keryx, Galena at TheStreet
Apr-02-16 12:13PM  Last Week's Best Healthcare ETF at Motley Fool
12:01AM  [$$] Charting the Market at Barrons.com
Mar-31-16 03:37PM  Buy Acadia, Alkermes, Starbucks and Verizon, Says Mott Capital Portfolio Manager at TheStreet +7.50%
02:55PM  Should Acadia, Alkermes Shares be at the Top of Your Buy List? at TheStreet
Mar-30-16 08:15PM  Why Lululemon Athletica, InterOil, and Acadia Pharmaceuticals Jumped Today at Motley Fool +9.24%
04:28PM  Its a shame I got stopped out
02:50PM  Why Acadia (ACAD) Stock is Still Soaring Today at TheStreet
02:36PM  4 Big-Volume Stocks to Trade for Big Gains at TheStreet
01:50PM  Why These Five Stocks Are Gaining Ground Today at Insider Monkey
11:00AM  Why Acadia Pharmaceuticals' Stock Is Rocketing Higher Today at Motley Fool
10:58AM  Acadia (ACAD) Stock Skyrockets, Parkinson's Disease Drug Backed by FDA Advisory Panel at TheStreet
10:34AM  Acadia Pharma Pops After Panel Backs Parkinsons Disease Drug
10:33AM  Acadia Soars as Key Drug Takes Big Step Closer to Approval at The Wall Street Journal
09:29AM  Stocks to Watch: Valeant, Acadia, OPKO Health, Lululemon at The Wall Street Journal
09:10AM  Acadia Posts Big Win With FDA Approval at 24/7 Wall St.
Mar-29-16 07:28PM  [$$] Acadia Gets FDA Panel Backing for Parkinson's Psychosis Treatment at The Wall Street Journal
07:06PM  XBI Mid-Cap News: Look Who Took a Beating on March 23
05:37PM  FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals NUPLAZID (Pimavanserin) for the Treatment of Psychosis Associated with Parkinsons Disease Outweigh the Risks at noodls
05:28PM  Gov't panel backs drug for delusions in Parkinson's patients
05:13PM  FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals NUPLAZID (Pimavanserin) for the Treatment of Psychosis Associated with Parkinsons Disease Outweigh the Risks Business Wire
03:53PM  FDA panel backs Acadia drug for psychosis linked to Parkinson's Reuters
03:48PM  A drug that could change the way Parkinson's disease is treated just got closer to approval
12:36PM  Acadia Pharma FDA Advisory Panel Live Blog at TheStreet
07:13AM  ACADIA Pharmaceuticals Stock Trading Halted Today at noodls
07:05AM  ACADIA Pharmaceuticals Stock Trading Halted Today Business Wire
Mar-28-16 05:08PM  Why did Acadia Pharma (ACAD) Gained 17% on the Day? +17.23%
04:06PM  Why Acadia Pharmas Shares Are Popping Today at Fortune
01:22PM  7 Stocks Seeing Big Volume Today -- and How You Should Trade Them Now at TheStreet
01:00PM  Why Are These Five Stocks In Spotlight Today? at Insider Monkey
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRAY MARY ANNDirectorJun 07Option Exercise9.0416,637150,398149,476Jun 09 05:28 PM
Iversen Leslie LDirectorApr 18Option Exercise1.7533,69758,97069,824Apr 20 05:37 PM
Iversen Leslie LDirectorApr 18Sale33.5333,6971,129,99936,127Apr 20 05:37 PM
GRAY MARY ANNDirectorApr 07Option Exercise1.33132,839176,600132,839Apr 07 08:27 PM
BAKER BROS. ADVISORS LPDirectorApr 01Buy28.52302,9008,638,57221,167,398Apr 01 04:21 PM
BAKER BROS. ADVISORS LPDirectorMar 31Buy27.21683,64418,601,18020,894,327Apr 01 04:21 PM
BAKER BROS. ADVISORS LPDirectorMar 30Buy25.94462,54612,000,0562,799,646Apr 01 04:21 PM
Baity GlennEVP AND GCMar 02Option Exercise15.377,000107,59069,921Mar 04 04:54 PM
Baity GlennEVP AND GCMar 02Sale20.807,000145,58062,921Mar 04 04:54 PM
14159, L.P.DirectorJan 07Buy29.002,586,20674,999,97420,278,008Jan 08 06:07 PM
Iversen Leslie LDirectorNov 11Option Exercise7.8630,000235,66966,127Nov 13 05:45 PM
Iversen Leslie LDirectorNov 11Sale36.0130,0001,080,32736,127Nov 13 05:45 PM
Iversen Leslie LDirectorAug 19Option Exercise11.008,50093,50036,127Aug 21 04:26 PM
Iversen Leslie LDirectorAug 19Option Exercise11.008,50093,50036,127Aug 21 04:26 PM
KAPLAN LESTER J PH DDirectorAug 11Option Exercise11.008,50093,50017,000Aug 13 05:10 PM